Black Diamond Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $9.9 million, a slight improvement from a net loss of $10.6 million in the same period last year. For the first half of 2026, the company recorded a net loss of $18.9 million, a significant decline compared to a net income of $46 million for the first half of 2025, which included a one-time license revenue of $70 million from a licensing agreement with Servier Pharmaceuticals. The company did not generate any license revenue in the first half of 2026, reflecting a strategic shift as it focuses on advancing its clinical programs.
Total operating expenses for the second quarter of 2026 were $12.1 million, down from $13.4 million in the prior year, primarily due to reduced research and development costs, which fell to $7.4 million from $9.3 million. This decrease was attributed to the completion of certain clinical trial phases for its lead product candidate, silevertinib, which targets non-small cell lung cancer (NSCLC) and glioblastoma (GBM). General and administrative expenses increased slightly to $4.7 million, driven by higher intellectual property-related costs.
As of June 30, 2026, Black Diamond Therapeutics reported total assets of $125 million, down from $143 million at the end of 2025. The company’s cash and cash equivalents decreased to $19.2 million from $21.8 million, while investments also saw a decline. The accumulated deficit increased to $483.7 million, reflecting the ongoing investment in research and development without corresponding revenue generation. The company’s total liabilities were reported at $28.9 million, a decrease from $30.8 million at the end of 2025.
Strategically, Black Diamond continues to advance its clinical programs, particularly silevertinib, which is currently in Phase 2 trials for both NSCLC and GBM. The company has initiated a randomized Phase 2 trial for GBM, with the first patient dosed in May 2026. The company is also exploring potential partnerships to further develop its pipeline. Looking ahead, Black Diamond anticipates that its existing cash and investments will be sufficient to fund operations into the second half of 2028, although it will need to secure additional funding to support ongoing clinical trials and operational costs. The company remains focused on advancing its product candidates while navigating the challenges of the biotechnology landscape.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov